Global Arthropod-borne Viral Infections Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Test Type;

Molecular Testing, Serological Testing, Antigen Testing, and Culture Testing

By Infection Type;

Dengue Virus, Zika Virus, West Nile Virus, and Chikungunya Virus

By Sample Type;

Blood, Urine, Saliva, and Tissue

By End User;

Hospitals, Public Health Laboratory, Diagnostic Centers, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn525551806 Published Date: June, 2025 Updated Date: July, 2025

Arthropod-borne Viral Infections Testing Market Overview

Arthropod-borne Viral Infections Testing Market (USD Million)

Arthropod-borne Viral Infections Testing Market was valued at USD 11,632.80 million in the year 2024. The size of this market is expected to increase to USD 21,292.53 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.0%.


Global Arthropod-borne Viral Infections Testing Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 9.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)9.0 %
Market Size (2024)USD 11,632.80 Million
Market Size (2031)USD 21,292.53 Million
Market ConcentrationMedium
Report Pages344
11,632.80
2024
21,292.53
2031

Major Players

  • Abbott Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • QIAGEN
  • Siemens Healthineers
  • Hologic
  • Cepheid
  • BD
  • Danaher Corporation

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Arthropod-borne Viral Infections Testing Market

Fragmented - Highly competitive market without dominant players


The Arthropod-borne Viral Infections Testing Market is expanding rapidly as diseases like dengue, Zika, and chikungunya continue to spread. Urbanization, travel, and climate shifts have driven up infection rates, making diagnostic testing more critical than ever. Around 60% of infectious outbreaks in warm climates are now traced to arthropod vectors, underscoring the importance of enhanced diagnostic efforts.

Technology-Driven Improvements in Diagnostics
Innovations in molecular and serological testing are revolutionizing how vector-borne viruses are diagnosed. Tools like RT-PCR and ELISA have boosted diagnostic accuracy by over 70%, significantly improving early detection. Meanwhile, point-of-care testing adoption is rising, offering faster results and improved outbreak management.

Emphasis on Early and Preventive Testing
The shift toward early-stage diagnosis is reshaping patient care in this space. Early testing has been shown to cut hospitalization rates by about 35%, leading healthcare providers to integrate these diagnostics more widely into treatment protocols. This proactive approach enhances outcomes and lowers healthcare costs.

Innovation through Collaboration
Collaboration is driving a new wave of diagnostic innovation. Over 45% of current R&D in this market focuses on multiplex testing platforms that detect multiple viruses simultaneously. These advancements are setting a new standard for efficiency, scalability, and adaptability in the fight against arthropod-borne viral infections.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Test Type
    2. Market Snapshot, By Infection Type
    3. Market Snapshot, By Sample Type

    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Arthropod-borne Viral Infections Testing Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing incidence of viral infections
        2. Technological advancements in diagnostic tools
        3. Growing awareness about preventive healthcare
        4. Rising demand for early detection
      2. Restraints
        1. High cost of testing procedures
        2. Limited accessibility in rural areas
        3. Regulatory challenges and compliance issues
        4. Lack of skilled healthcare professionals
      3. Opportunities
        1. Emerging markets in developing countries
        2. Development of rapid testing kits
        3. Expansion of telemedicine services
        4. Collaborations for research and development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Arthropod-borne Viral Infections Testing Market, By Test Type, 2021 - 2031 (USD Million)
      1. Molecular Testing
      2. Serological Testing
      3. Antigen Testing
      4. Culture Testing
    2. Arthropod-borne Viral Infections Testing Market, By Infection Type, 2021 - 2031 (USD Million)
      1. Dengue Virus
      2. Zika Virus
      3. West Nile Virus
      4. Chikungunya Virus
    3. Arthropod-borne Viral Infections Testing Market, By Sample Type, 2021 - 2031 (USD Million)
      1. Blood

      2. Urine

      3. Saliva

      4. Tissue

    4. Arthropod-borne Viral Infections Testing Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Public Health Laboratory
      3. Diagnostic Centers
      4. Others
    5. Arthropod-borne Viral Infections Testing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott Laboratories
      2. Roche Diagnostics
      3. Thermo Fisher Scientific
      4. Bio-Rad Laboratories
      5. QIAGEN
      6. Siemens Healthineers
      7. Hologic
      8. Cepheid
      9. BD
      10. Danaher Corporation
  7. Analyst View
  8. Future Outlook of the Market